As of 2026-03-15, the Relative Valuation of Protagonist Therapeutics Inc (PTGX) is (50.59) USD. This relative valuation is based on P/E multiples. With the latest stock price at 92.36 USD, the upside of Protagonist Therapeutics Inc based on Relative Valuation is -154.8%.
The range of the Relative Valuation is (47.67) - (55.50) USD.
Note: valuation result may not be accurate due to the company's negative earnings.
| Range | Selected | |
| Trailing P/E multiples | 22.9x - 28.3x | 25.6x |
| Forward P/E multiples | 22.2x - 26.7x | 23.0x |
| Fair Price | (47.67) - (55.50) | (50.59) |
| Upside | -151.6% - -160.1% | -154.8% |
| Date | P/E |
| 2026-03-13 | -44.37 |
| 2026-03-12 | -45.84 |
| 2026-03-11 | -46.35 |
| 2026-03-10 | -46.62 |
| 2026-03-09 | -46.43 |
| 2026-03-06 | -44.24 |
| 2026-03-05 | -43.91 |
| 2026-03-04 | -45.55 |
| 2026-03-03 | -43.86 |
| 2026-03-02 | -45.27 |
| 2026-02-27 | -44.23 |
| 2026-02-26 | -42.46 |
| 2026-02-25 | -41.84 |
| 2026-02-24 | -41.98 |
| 2026-02-23 | -41.60 |
| 2026-02-20 | -39.76 |
| 2026-02-19 | -39.91 |
| 2026-02-18 | -39.87 |
| 2026-02-17 | -39.61 |
| 2026-02-13 | -39.15 |
| 2026-02-12 | -39.36 |
| 2026-02-11 | -40.11 |
| 2026-02-10 | -40.29 |
| 2026-02-09 | -40.02 |
| 2026-02-06 | -40.59 |
| 2026-02-05 | -38.75 |
| 2026-02-04 | -40.02 |
| 2026-02-03 | -41.12 |
| 2026-02-02 | -39.89 |
| 2026-01-30 | -39.29 |
| 2026-01-29 | -38.30 |
| 2026-01-28 | -39.28 |
| 2026-01-27 | -39.91 |
| 2026-01-26 | -39.53 |
| 2026-01-23 | -39.92 |
| 2026-01-22 | -40.73 |
| 2026-01-21 | -40.30 |
| 2026-01-20 | -40.07 |
| 2026-01-16 | -39.39 |
| 2026-01-15 | -40.71 |
| 2026-01-14 | -40.94 |
| 2026-01-13 | -39.08 |
| 2026-01-12 | -38.55 |
| 2026-01-09 | -38.54 |
| 2026-01-08 | -38.53 |
| 2026-01-07 | -39.55 |
| 2026-01-06 | -39.52 |
| 2026-01-05 | -40.44 |
| 2026-01-02 | -41.88 |
| 2025-12-31 | -41.96 |